Objective: We sought to evaluate the efficacy and safety of vildagliptin, a new dipeptidyl peptidase-4 inhibitor, added to metformin during 24 weeks of treatment in patients with type 2 diabetes.

Study A was supported by Novartis, which supplied the vildagliptin and matching placebo tablets. Study B was funded by Merck Sharp & Dohme, which arranged the supply of metformin and placebo.

Review the side-effects of Vildagliptin as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority ...

Vildagliptin SR and Metformin SR tablets merge the potent mechanisms of vildagliptin and metformin to offer patients a comprehensive approach to managing their glycemic levels. Vildagliptin ...

A recent study has found that a single dose of the DPP-IV inhibitor vildagliptin caused a significant suppression of endogenous glucose production in patients with type 2 diabetes.

Details concerning the Vildagliptin combination medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ointments ...

Currently the branded versions of Vildagliptin controlled by Novartis are sold at prices between Rs 20 and Rs 28 per tablet. On E-pharmacy portal 1Mg - Natco Pharma and Vivifi Life Sciences have ...

(HealthDay)—The dipeptidyl peptidase-4 (DPP-4) inhibitors vildagliptin and sitagliptin have similar effects on incretin hormone secretion, according to a study published online June 14 in ...

The Indian drug price regulator has fixed the price of a tablet of anti-diabetes drug vildagliptin and metformin 50mg/500 mg at Rs 6.86. The generic versions cost around Rs 8-10 a tablet.

In contrast, in the group receiving 50 mg vildagliptin daily, more than two-thirds of patients experienced meaningful (37.8%) or marked (29.4%) improvement in glycemic control. In the group ...